Sudeep Pharma Ltd
Sudeep Pharma Ltd (SUDEEPPHRM) last traded at ₹1,123, a market capitalisation of ₹12,681 crore, on a P/E of 69.5. Over the past 52 weeks the stock has ranged between ₹524 and ₹1,189. Sudeep Pharma Ltd last reported results for the quarter ended Jun 2026, with sales of ₹158 crore and net profit of ₹41 crore. Figures are as of 25 Aug 2026 and are not real time.
Sudeep Pharma Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Sudeep Pharma Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹158 cr, up 26.4% from ₹125 cr a year earlier. Net profit was ₹41 cr, up 32.3% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 149 | 116 | 158 | 125 | 163 | 172 | 182 | 158 |
| Expenses | 85 | 76 | 99 | 81 | 107 | 112 | 120 | 103 |
| Operating profit | 63 | 39 | 59 | 44 | 55 | 60 | 63 | 55 |
| OPM % | 43% | 34% | 37% | 35% | 34% | 35% | 34% | 35% |
| Other income | 2 | 2 | 4 | 5 | 10 | 7 | 6 | 5 |
| Interest | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 2 |
| Depreciation | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Profit before tax | 62 | 38 | 58 | 44 | 60 | 62 | 63 | 54 |
| Tax % | 21% | 24% | 24% | 29% | 21% | 23% | 23% | 25% |
| Net profit | 49 | 29 | 44 | 31 | 47 | 48 | 49 | 41 |
| EPS (₹) | 128.13 | 2.95 | 4.54 | 3.17 | 4.71 | 4.20 | 4.33 | 3.59 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Sudeep Pharma Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 215 | 343 | 429 | 459 | 502 | 642 | 676 |
| Operating profit | 44 | 67 | 90 | 183 | 192 | 223 | 233 |
| OPM % | 20% | 20% | 21% | 40% | 38% | 35% | 34% |
| Net profit | 33 | 50 | 62 | 133 | 139 | 174 | 184 |
| EPS (₹) | 236.60 | 356.04 | 442.27 | 945.21 | 14.27 | 15.31 | 16.83 |
TTM is the trailing twelve months to the most recent quarter.
Sudeep Pharma Ltd growth and returns
- 10 Years
- %
- 5 Years
- 24%
- 3 Years
- 14%
- TTM
- 24%
- 10 Years
- %
- 5 Years
- 39%
- 3 Years
- 40%
- TTM
- 20%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- %
- 10 Years
- %
- 5 Years
- 32%
- 3 Years
- 32%
- Last Year
- 25%
Sudeep Pharma Ltd shareholding pattern
Promoters held 76.16% at Jun 2026, broadly unchanged since Dec 2025. FIIs 1.81% and DIIs 15.64%.
| % held | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Promoters | 76.16% | 76.16% | 76.16% |
| FIIs | 1.67% | 1.55% | 1.81% |
| DIIs | 17.59% | 18.11% | 15.64% |
| Public | 4.57% | 4.18% | 6.39% |
| No. of shareholders | 43,599 | 36,503 | 35,695 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Sudeep Pharma Ltd corporate filings
- Submission of Earnings Call Transcript for the call held on 05.08.2026Company Updatehigh impact
Cruxal's analysis: Sudeep Pharma Limited reported a strong start to FY27 with consolidated revenue of INR…
Read the full analysis - General UpdateCompany Updatelow impact
Cruxal's analysis: Sudeep Pharma Ltd has released a general update filing dated August 6, 2026. The…
Read the full analysis - Submission of Audio Recording of Earnings Call held on 05.08.2026Company Updatelow impact
Cruxal's analysis: Sudeep Pharma Limited has formally filed the audio recording of its Q1 FY27 earnings call…
Read the full analysis - Submission of E-voting and Scrutinizer''s Report for the 37th Annual General Meeting held on 04.08.2026AGM/EGMmedium impact
Cruxal's analysis: Sudeep Pharma Limited has successfully concluded its 37th Annual General Meeting held on…
Read the full analysis - Submission of newspaper publication of Financials as on 30.06.2026Company Updatelow impact
Cruxal's analysis: Sudeep Pharma Ltd has fulfilled its regulatory obligation under Regulation 30 of the SEBI…
Read the full analysis - Submission of revised Investors PresentationCompany Updatehigh impact
Cruxal's analysis: Sudeep Pharma Limited delivered a resilient Q1 FY27 performance, reporting revenue of…
Read the full analysis - Submission of Investors PresentationCompany Updatehigh impact
Cruxal's analysis: Sudeep Pharma Limited delivered a resilient Q1 FY27 performance, reporting revenue of…
Read the full analysis - Submission of Investors PresentationCompany Updatehigh impact
Cruxal's analysis: Sudeep Pharma Limited delivered a resilient Q1 FY27 performance, reporting revenue of…
Read the full analysis - Submission of Outcome of Board MeetingBoard Meetinghigh impact
Cruxal's analysis: Sudeep Pharma Limited has announced robust consolidated financial results for the first…
Read the full analysis - Submission of proceedings of the 37th Annual General Meeting held on 4th August 2026AGM/EGMhigh impact
Cruxal's analysis: Sudeep Pharma Limited has announced robust financial results for the fiscal year 2025-26…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Sudeep Pharma Ltd
Cruxal reads every Sudeep Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.